Pancreatic Cancer Research

ResearcherUniversity of ZurichActive in the last 2 years

Matthias Gückenberger

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7146-9071; OpenAlex author ID A5023510680. Sources: ClinicalTrials.gov.

Their work

Papers
6 (first author 1, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 trial · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 6

  1. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Adenocarcinoma: A Systematic Review and Meta-Analysis of Prospective Trials. Co-author DOI 10.1016/j.prro.2026.04.015↗
  2. Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma using different imaging modalities. Co-author DOI 10.1007/s00066-023-02085-7↗
  3. MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open rand… Co-author DOI 10.1186/s13014-022-01988-6↗
  4. [Role of stereotactic body radiation therapy for unresected pancreatic cancer]. First author DOI 10.1007/s00066-018-1331-1↗
  5. Potential dosimetric benefits of adaptive tumor tracking over the internal target volume concept for stereotactic body radiation therapy of pancreatic cancer. Co-author DOI 10.1186/s13014-017-0906-9↗
  6. Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stere… Last author DOI 10.1007/s00066-016-1053-1↗

Trials 1

  1. Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) Principal investigator NCT04498767↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Piet Ost · 1 shared trial, 2021 · strength 0.42
  2. K. Liang Zeng · 1 shared paper, 2026 · strength 0.26
  3. Simon Shek-Man Lo · 1 shared paper, 2026 · strength 0.26
  4. Marta Scorsetti · 1 shared paper, 2026 · strength 0.26
  5. Sylvia S. W. Ng · 1 shared paper, 2026 · strength 0.26
  6. Matea Pavic · 2 shared papers, 2022–2023 · strength 0.25
  7. Thomas Baptist Brunner · 2 shared papers, 2016–2023 · strength 0.20
  8. Jana Schaule · 1 shared paper, 2018 · strength 0.17
  9. Jürgen Debus · 1 shared paper, 2022 · strength 0.13
  10. Marlies Vornhülz · 1 shared paper, 2022 · strength 0.13
  11. Georg Beyer · 1 shared paper, 2022 · strength 0.13
  12. Julia V. Mayerle · 1 shared paper, 2022 · strength 0.13
  13. Ralph Fritsch · 1 shared paper, 2022 · strength 0.13
  14. Sophie Dobiasch · 1 shared paper, 2023 · strength 0.12
  15. Eleni Gkika · 1 shared paper, 2023 · strength 0.12
  16. Stefan Lautenschläger · 1 shared paper, 2023 · strength 0.12
  17. Fabian Eberle · 1 shared paper, 2023 · strength 0.12
  18. Falk Roeder · 1 shared paper, 2023 · strength 0.12
  19. Cédric Michael Panje · 1 shared paper, 2016 · strength 0.08
  20. Stephanie Tanadini‐Lang · 1 shared paper, 2017 · strength 0.07
  21. Konstantina Karava · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.